Online citations, reference lists, and bibliographies.
Referencing for people who value simplicity, privacy, and speed.
Get Citationsy
← Back to Search

Early Versus Delayed Androgen Deprivation For Prostate Cancer: New Fuel For An Old Debate.

C. Ryan, E. Small
Published 2005 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
The purpose of this review is to discuss the recent increase in data supporting the use of androgen ablation early in the clinical course for patients with nonmetastatic prostate cancer. We systematically reviewed recent publications that report on the use of androgen deprivation (AD) in nonmetastatic prostate cancer patients from the 2003 and 2004 proceedings of the American Society of Clinical Oncology, the 2003 and 2004 proceedings of the American Urological Association as well as published literature from 2003 to 2005. Five recently published mature randomized trials of AD plus local therapy were evaluated plus two large data sets on the use of AD for patients with serologic relapse after local therapy. Four mature randomized studies demonstrate an overall survival benefit to the use of AD in conjunction with definitive local therapy (three with radiation and one with surgery). One retrospective analysis suggests that AD administered early after serologic progression improves overall survival, and one retrospective analysis shows a reduction in metastasis-free survival but has not yet shown an overall survival benefit. For patients with nonmetastatic prostate cancer with high-risk features, as well as those for serologic relapse, the use of AD before the development of metastatic disease is supported by long-term outcomes from a series of clinical trials. Consideration of AD is therefore warranted early in the clinical course of high-risk patients.
This paper references
10.1093/JNCI/90.10.766
A Preoperative Nomogram for Disease Recurrence Following Radical Prostatectomy for Prostate Cancer
M. Kattan (1998)
10.1056/NEJMOA030660
The influence of finasteride on the development of prostate cancer.
I. Thompson (2003)
10.1016/S0022-5347(05)64652-6
Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.
W. See (2002)
10.1001/JAMA.281.17.1591
Natural history of progression after PSA elevation following radical prostatectomy.
C. Pound (1999)
10.1200/JCO.2004.22.90140.4552
Duration of response to androgen deprivation therapy and survival after subsequent biochemical relapse in men initially treated with radical prostatectomy.
F. Bianco (2004)
10.1056/NEJMOA041318
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
D. Petrylak (2004)
10.1001/JAMA.1997.03540420041027
Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.
A. Partin (1997)
10.1016/S0022-5347(05)65393-1
Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results.
M. Soloway (2002)
10.1016/S0360-3016(00)01516-9
Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate.
C. Lawton (2001)
10.1200/JCO.2004.99.160
Inflammatory breast carcinoma: the sphinx of breast cancer research.
M. Cristofanilli (2004)
10.1056/NEJMOA040720
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
I. Tannock (2004)
10.1200/JCO.1997.15.3.1013
Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31.
M. Pilepich (1997)
10.1158/1078-0432.CCR-04-0750
Associations between Serum Testosterone Fall and Cognitive Function in Prostate Cancer Patients
E. Salminen (2004)
10.1111/J.1464-410X.1995.TB07389.X
High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer.
M. Cher (1995)
10.1046/J.1464-410X.1997.D01-6840.X
Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group.
R. Adib (1997)
10.1002/cncr.1990.66.s5.1039
Leuprolide With and Without Flutamide in Advanced Prostate Cancer
E. Crawford (1990)
10.1097/01.JU.0000057795.97626.66
Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails.
W. Kassouf (2003)
10.1001/JAMA.292.7.821
6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
A. D'Amico (2004)
10.1001/JAMA.280.11.969
Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer
A. D'Amico (1998)
10.3322/canjclin.22.4.232
Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate
C. Huggins (1972)
10.1200/JCO.2003.11.102
Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.
Mary-Ellen Taplin (2003)
10.1016/S0022-5347(05)65971-X
Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects.
M. Gleave (2001)
10.1200/JCO.2004.06.037
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).
E. Small (2004)
10.1016/J.UROLOGY.2003.10.063
Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer.
M. Smith (2004)
10.1093/JNCI/DJG043
Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
A. D'Amico (2003)
10.1097/01.JU.0000113794.34810.D0
Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.
J. Moul (2004)
10.1097/00005392-199904010-00701
IMMEDIATE HORMONAL THERAPY VS. OBSERVATION FOR NODE POSITIVE PROSTATE CANCER FOLLOWING RADICAL PROSTATECTOMY AND PELVIC LYMPHADENECTOMY: A RANDOMIZED PHASE III EASTERN COOPERATIVE ONCOLOGY GROUP/INTER GROUP TRIAL
E. Messing (1999)
10.1016/S0090-4295(99)00471-9
Clinical states in prostate cancer: toward a dynamic model of disease progression.
H. Scher (2000)
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.
M. E. Taplin (1999)
10.1016/S0022-5347(18)37696-1
434: Timing of LHRH Treatment After PSA Failure in Prostate Cancer Patients: A Survival Analysis from the Capsure Database
K. Wallace (2004)
10.1016/S0360-3016(00)00577-0
Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials.
Roach M 3RD (2000)
10.1016/S0022-5347(17)41100-1
Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies.
D. Byar (1988)
10.1016/S0140-6736(02)09408-4
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial
M. Bolla (2002)
10.1200/JCO.2005.08.141
Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31.
C. Lawton (2005)
10.1210/JCEM.87.2.8299
Changes in body composition during androgen deprivation therapy for prostate cancer.
M. Smith (2002)



This paper is referenced by
10.1016/J.EURURO.2008.09.033
Re: Timing of Androgen Deprivation Therapy and Its Impact on Survival after Radical Prostatectomy: A Matched Cohort Study
S. Shariat (2009)
10.1016/j.eururo.2015.12.045
Limitations of Prostate-specific Antigen Testing After a Prostate Cancer Diagnosis.
Megan E V Caram (2016)
10.1016/B978-1-4557-2758-2.00029-9
Chapter 29 – Hormone Responsive Cancers
R. Santen (2014)
10.1016/B978-1-4160-6911-9.00109-2
Hormone Therapy for Prostate Cancer
J. Nelson (2012)
10.1016/J.EURURO.2006.08.043
Antiandrogens in the treatment of prostate cancer.
M. Wirth (2007)
10.1371/journal.pone.0020034
Genistein Increases Epidermal Growth Factor Receptor Signaling and Promotes Tumor Progression in Advanced Human Prostate Cancer
H. Nakamura (2011)
10.1097/01.NURSE.0000320359.09574.5c
Caring for a patient with metastatic prostate cancer.
J. Held-Warmkessel (2008)
10.7150/ijbs.8756
Conversion of Androgen Receptor Signaling From a Growth Suppressor in Normal Prostate Epithelial Cells to an Oncogene in Prostate Cancer Cells Involves a Gain of Function in c-Myc Regulation
D. V. Vander Griend (2014)
10.1002/PROS.20655
Regulation of global gene expression in the bone marrow microenvironment by androgen: Androgen ablation increases insulin‐like growth factor binding protein‐5 expression
C. Xu (2007)
10.1186/s13014-014-0245-z
Less advanced disease at initiation of salvage androgen deprivation therapy is associated with decreased mortality following biochemical failure post-salvage radiation therapy
C. Foster (2014)
10.4065/82.2.243
Prostate cancer: a practical approach to current management of recurrent disease.
J. Walczak (2007)
Zentrale, periphere und Second-line-Hormontherapie
Philipp Maletzki (2017)
10.1111/j.1464-410X.2006.06357_3.x
SIDE‐EFFECTS OF TREATMENTS FOR LOCALLY ADVANCED PROSTATE CANCER
R. Gardiner (2006)
10.4068/cmj.2020.56.2.115
The Relationships between Survivals and Early Salvage Androgen Deprivation Therapy for Non-Organ Confined Prostate Cancer after Radical Prostatectomy
Jae Yeo Park (2020)
10.1111/j.1464-410X.2006.06357_6.x
IMMEDIATE ADMINISTRATION OF INTRAVESICAL MITOMYCIN C AFTER TUMOUR RESECTION FOR SUPERFICIAL BLADDER CANCER
D. Besarani (2006)
10.1111/j.1464-410X.2006.06357_4.x
NANOTECHNOLOGY: POTENTIAL APPLICATIONS IN UROLOGY
A. Tsiouris (2006)
10.1007/978-1-4614-6176-0_17
Impact of genetic targets on prostate cancer therapy.
Hassan Sheikh (2013)
10.1007/S12094-009-0318-X
Predictive modelling in hormone-refractory prostate cancer (HRPC)
J. Bellmunt (2009)
10.1186/1471-2490-14-81
Ultra-early versus early salvage androgen deprivation therapy for post-prostatectomy biochemical recurrence in pT2-4N0M0 prostate cancer
S. Taguchi (2014)
10.1093/JJCO/HYM105
Decision analyses in consideration of treatment strategies for patients with biochemical failure after curative therapy on clinically localized prostate cancer in the prostate-specific antigen era.
F. Shimizu (2007)
10.3349/ymj.2018.59.5.580
Impact of Early Salvage Androgen Deprivation Therapy in Localized Prostate Cancer after Radical Prostatectomy: A Propensity Score Matched Analysis
J. W. Park (2018)
10.1016/j.critrevonc.2013.11.003
Salvage therapy of small volume prostate cancer nodal failures: a review of the literature.
B. De Bari (2014)
10.1007/S11934-007-0013-9
The spectrum of prostate cancer care: From curative intent to palliation
A. S. Ali (2007)
10.1016/j.ijrobp.2012.03.001
Early salvage hormonal therapy for biochemical failure improved survival in prostate cancer patients after neoadjuvant hormonal therapy plus radiation therapy--a secondary analysis of irish clinical oncology research group 97-01.
A. Mydin (2013)
10.14310/horm.2002.1727
Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on metabolic complications
V. Tzortzis (2017)
ANALYSIS OF ENDOTHELIN DURING ANDROGEN DEPRIVATION: IMPLICATIONS FOR PROSTATE CANCER PROGRESSION
Jason M. D'Antonio (2007)
10.1111/j.1464-410X.2006.06357_1.x
TREATMENT OF LOCALIZED PROSTATE CANCER USING HIGH‐INTENSITY FOCUSED ULTRASOUND
S. Ahmed (2006)
10.1186/s12894-020-00593-7
Survival and mortality of elderly men with localized prostate cancer managed with primary androgen deprivation therapy or by primary observation
Heikki A Seikkula (2020)
10.1002/PON.1206
Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy
W. Pirl (2008)
10.1007/S12032-007-0017-9
Current perspectives in the treatment of advanced prostate cancer
V. Valdespino (2007)
10.1200/JCO.2006.05.8420
How early is early: androgen deprivation for prostate-specific antigen relapse in prostate cancer.
G. Duchesne (2006)
Overexpression of Androgen Receptor in Prostate Cancer
A. Urbanucci (2012)
See more
Semantic Scholar Logo Some data provided by SemanticScholar